Back to News & Events

Call for Applications-Spring 2023 Innovation Bootcamp

Long Island New York I-Corps Hub – Innovation Bootcamp Spring 2023 Program

This Innovation Bootcamp Program will teach scientists, inventors and first-time entrepreneurs the Lean Launchpad Methodology – Customer Discovery through 20 interviews, Agile Development roadmapping, and the Business Model Canvas – specifically Value Propositions and Customer Segments

Kickoff Session: Tuesday, February 14, 9:00 AM – 4:00 PM (Online)
Mid Session: Friday, February 14, 9:15 AM – 4:00 PM (Online) and
Finale Session: Friday, March 3, 9:15 AM – 3:00 PM (Room 109, R&D Park Research and Support Services)

Applications are being reviewed NOW on a rolling basis until 11:59 PM Friday, Feb 3, 2023. Limited space is available – apply early! https://forms.gle/RM8WRrN3VuGVCMgP8

Teams of 1+ faculty, staff, etc. from any university, national lab, or community teams with an Innovation or Research Idea should be STEAM focused are encouraged to apply. Must be able to attend all 3 scheduled workshops and dedicate time outside of the sessions to do customer discovery interviews
For full details and eligibility requirements, please visit https://tinyurl.com/SBUBootcampSpring23

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2237 [post_author] => 3 [post_date] => 2016-06-07 15:14:28 [post_date_gmt] => 2016-06-07 15:14:28 [post_content] => Traverse Biosciences has announced that it has secured $500,000 in convertible debt financing to support operations and advance product development efforts. The seed financing was led by Excell Partners, with matching funds from a number of individual accredited angel investors. The Research Foundation for the State of New York (RF/SUNY) also participated in the financing, as part of an exclusive license and option agreement executed last year that gave Traverse Biosciences access to the relevant intellectual property for use in animal and human health. Traverse Biosciences, which began when CEO Joseph Scaduto was serving as a BioEntrepreneur-in-Residence for the Center for Biotechnology, is working to commercialize its proprietary library of Stony Brook University invented chemically-modified curcumins for the treatment of chronic inflammatory conditions and cancers affecting humans and animals. Read more about Traverse and the recent financing:     [post_title] => Traverse Biosciences Secures $500k Seed Financing [post_excerpt] => Traverse Biosciences announced that it has secured $500,000 in convertible debt financing to support operations and advance product development efforts. The seed financing was led by Excell Partners, with matching funds from a number of individual accredited angel investors. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => traverse-biosciences-secures-500k-seed-financing [to_ping] => [pinged] => [post_modified] => 2016-06-07 15:14:28 [post_modified_gmt] => 2016-06-07 15:14:28 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2237 [menu_order] => 177 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2984 [post_author] => 4 [post_date] => 2018-06-22 14:46:11 [post_date_gmt] => 2018-06-22 14:46:11 [post_content] => The Center for Biotechnology at Stony Brook University has been selected as one of eight accelerators in the nation by the U.S. Department of Health and Human Services (HHS) to drive innovation in lifesaving medical technologies that solve challenging problems spanning modern health security threats and daily medical care. Accelerators will scout out innovative technologies and products that can be developed to solve healthcare challenges that extend beyond traditional vaccine and drug development. To assist startups and other businesses in developing their technologies and products, accelerators will connect them with essential product development and business support services. This support could position innovative technologies and products for follow-on investment from the public or private sectors. A new HHS unit called DRIVe – part of the Biomedical Advanced Research and Development Authority (BARDA) at the HHS Office of the Assistant Secretary for Preparedness and Response – will oversee the accelerator network and is recruiting a nonprofit partner that can work with private investors to fund innovative technologies and products to solve these and other systemic health security challenges. DRIVe also can invest in the projects using quick, streamlined funding methods. Read the full HHS press release here.  [caption id="attachment_2985" align="alignnone" width="584"] DRIVe Announcement at 2018 BIO International Convention. L to R, Rick Bright, Director, BARDA, Diane Fabel, Director Operations, Stony Brook Center for Biotechnology, Patricia Beckmann, President and Executive Director and Jessica Roberto, Associate Director, Life Science Washington Institute, and Robert Kadleck, Assistant Secretary for Preparedness & Response, HHS.[/caption] Additional Media Coverage: Forbes – June 8, 2018 “An Unlikely Biotech Investor: The Government” Newsday – June 5, 2018 “Stony Brook center tapped for federal anti-infection program” Innovate Long Island – June 5, 2018 “SBU Joins Elite HHS Business-Development Task Force” [post_title] => CFB Selected as DRIVe Accelerator [post_excerpt] => The Center for Biotechnology has been selected as one of eight accelerators in the nation by the U.S. Department of Health and Human Services (HHS). [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-selected-as-drive-accelerator [to_ping] => [pinged] => [post_modified] => 2018-08-20 14:56:27 [post_modified_gmt] => 2018-08-20 14:56:27 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2984 [menu_order] => 121 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2930 [post_author] => 3 [post_date] => 2018-01-30 19:19:22 [post_date_gmt] => 2018-01-30 19:19:22 [post_content] => The latest CFB Newsletter has been released - Catch up on client financings, newcos, expansions, and other happenings here. Be sure to follow us on Twitter, LinkedIn and Facebook for the latest Center news. [post_title] => Winter 2018 Newsletter [post_excerpt] => The latest CFB Newsletter has been released – Catch up on client financings, newcos, expansions, and other happenings. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => winter-2018-newsletter [to_ping] => [pinged] => [post_modified] => 2018-02-02 18:36:31 [post_modified_gmt] => 2018-02-02 18:36:31 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2930 [menu_order] => 126 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Traverse Biosciences Secures $500k Seed Financing

More Information

CFB Selected as DRIVe Accelerator

More Information

Winter 2018 Newsletter

More Information